McDermott Will & Emery assisted DBV Technologies in the transaction. DBA Associés also acted for DBV Technologies. The Cooley law firm acted for DBV Technologies on American law aspects. Gide and Goodwin advised the banks
DBV Technologies completed the $153 million capital increase in connection with (i) a public offering of common shares in the form of American Depositary Shares (“ADS”) in the United States, Canada and certain countries outside of Europe at a price of US$10.25 per ADS, and (ii) an offering of common shares exclusively to qualified investors in Europe (including in France). The Company’s ADSs are admitted to trading on the Nasdaq Global Select Market under the symbol “DBVT” and the Company’s common shares are admitted to trading on the Euronext Paris under the symbol “DBV”.
Gide in France and Goodwin in the United States acted for lead banks and joint bookrunners Goldman Sachs and Citigroup.
DBV Technologies is a global clinical stage biopharmaceutical company dedicated to the development of safe and effective food allergy treatments.
McDermott Will & Emery acted for DBV Technologies with a team led by partners Emmanuelle Trombe (Picture) and Bertrand Delafaye, and including associates Stephan de Groër, Baptiste Tigaud and Mathilde Peschard.
Gide advised Goldman Sachs, Citigroup, JMP Securities, H.C. Wainwright & Co. et Kempen & Co with a team including Arnaud Duhamel, Guilhem Richard, Aude-Laurène Dourdain and Mariléna Gryparis.
Involved fees earner: Aude-Laurène Dourdain – Gide Loyrette Nouel; Arnaud Duhamel – Gide Loyrette Nouel; Marie-Hélène Gryparis – Gide Loyrette Nouel; Guilhem Richard – Gide Loyrette Nouel; Stephan de Groër – McDermott Will & Emery; Bertrand Delafaye – McDermott Will & Emery; Mathilde Peschard – McDermott Will & Emery; Emmanuelle Trombe – McDermott Will & Emery;